Development of carbohydrate based anticancer agents
CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylati...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SweetAim
Selective glycoimmuno targeting for cancer therapy
1M€
Cerrado
GlycoTherapy
New frontiers in advanced glycotherapy for cancer
2M€
Cerrado
GlycoMap
Integrated Glycomics for Cancer Precision Medicine
227K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry and cancer immunology we targeted the cancer-cell protecting carbohydrate coat, hampering the cancer's ability to grow and metastasize. In this project, we aim to deliver a technical and commercial proof-of-concept for targeting the glycosylation of cancer cells to ultimately enable clinical studies